February 2004
Can Pfizer Deliver?
Despite skyrocketing R&D spending, pharmaceutical companies' drug output has slowed dramatically. Pfizer is counting on creative new technologies to keep the pipeline full.
By David Rotman
Don't bother mentioning "the genomic revolution" these days in the halls of Pfizer's sprawling research and development facility in Groton, CT. Yes, the company's scientists will acknowledge, the latest techniques in genomics and proteomics are interesting and occasionally useful; just don't expect them to revolutionize drug discovery anytime soon. And as Pfizer's R&D executives are equally hasty to point out, the new technologies are expensive-very expensive.
![]() | Select from the choices above to read the entire article. |
Customer Service
|
Magazine Services
|
Subscribe
|
Other
|
Advertise
|


